Deutsche Bank Ag\ Next Cure, Inc. Transaction History

Deutsche Bank Ag\

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 04, 2021	SELL	$6.74 - $8.02 $47,928 - $57,030	-7,111 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$7.6 - $10.28 $374,543 - $506,618	-49,282 Reduced 87.39%	7,111 $57,000
Q1 2021 May 13, 2021	SELL	$9.81 - $13.88 $57,996 - $82,058	-5,912 Reduced 9.49%	56,393 $564,000
Q4 2020 Feb 16, 2021	SELL	$9.47 - $12.43 $4.63 Million - $6.07 Million	-488,602 Reduced 88.69%	62,305 $678,000
Q3 2020 Nov 12, 2020	BUY	$8.15 - $21.17 $4.42 Million - $11.5 Million	542,741 Added 6646.35%	550,907 $4.85 Million

Q2 2020 Aug 13, 2020	BUY	$21.19 - $40.2 $64,036 - $121,484	3,022 Added 58.75%	8,166 $175,000
Q1 2020 May 14, 2020	SELL	$32.32 - $58.37 $937 - $1,692	-29 Reduced 0.56%	5,144 $191,000
Q4 2019 Feb 14, 2020	BUY	$25.0 - $92.22 $108,025 - $398,482	4,321 Added 507.16%	5,173 $290,000
Q3 2019 Nov 14, 2019	SELL	$15.73 - $41.6 $20,873 - $55,203	-1,327 Reduced 60.9%	852 $25,000
Q2 2019 Aug 14, 2019	BUY	$14.16 - $20.64 $30,854 - $44,974	2,179 New	2,179 $32,000

783K

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $263M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.